Pasithea Therapeutics Corp. (KTTA) — Analyst outlook / Analyst consensus target is. Based on 1 analyst ratings, the consensus is bullish — 1 Buy.
The consensus price target is $3.00, representing an upside of 315.5% from the current price $0.72.
Analysts estimate Earnings Per Share (EPS) of $-1.50 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-12.69 vs est $-1.50 (missed -745.7%). 2025: actual $-2.91 vs est $-0.68 (missed -327.9%). Analyst accuracy: 18%.
KTTA Stock — 12-Month Price Forecast
$3.00
▲ +315.51% Upside
Average Price Target
Based on 1 Wall Street analysts offering 12-month price targets for Pasithea Therapeutics Corp., the price target is $3.00.
The average price target represents a +315.51% change from the last price of $0.72.
KTTA Analyst Ratings
Buy
Based on 1 analysts giving stock ratings to Pasithea Therapeutics Corp. in the past 3 months
EPS Estimates — KTTA
18%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$12.69
vs Est –$1.50
▼ 88.2% off
2025
Actual –$2.91
vs Est –$0.68
▼ 76.6% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — KTTA
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
